TrialLeukemia research2014

Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia.

William E Pierceall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.